Advertisement

Clinical and Translational Imaging

, Volume 6, Issue 3, pp 151–168 | Cite as

18F-FDG-PET and MRI in autoimmune encephalitis: a systematic review of brain findings

  • Silvia Morbelli
  • Marco Zoccarato
  • Matteo Bauckneht
  • Mariagiulia Anglani
  • Diego Cecchin
Systematic Review
Part of the following topical collections:
  1. Neuroimaging

Abstract

Introduction

In the diagnostic assessment of autoimmune encephalitis (AE) associated with antineural antibody (Ab) imaging with 18F-fluorodeoxyglucose (FDG), positron emission tomography (PET) was initially only used to screen for occult malignancies in paraneoplastic cases. Today accumulating evidence also supports the use of PET imaging for the objective assessment of metabolic changes in the brain of patients with AE. On the other hand, magnetic resonance imaging (MRI) of the brain reveals a variable picture depending on the specific syndrome and associated antibody, and may be normal in a sizable proportion of patients.

Acquisition of evidence

Among all the articles retrieved, we selected only studies and case series describing 18F-PET/CT, or multimodal imaging assessments (with both PET/CT and MRI performed in the same patient) on at least five patients with AE confirmed by the presence of antineural Ab. Studies describing MRI but not PET/CT findings on at least 20 cases were also included to strengthen the morphological considerations.

Summary of evidence

We summarize the findings in the literature, commenting on studies involving the use of FDG-PET/CT in patients with AE, focusing on the added value and unsolved issues of using FDG-PET as opposed to MRI, and discussing them in the context of the available diagnostic criteria for AE. We also describe neuroimaging (PET and MRI) differences between AE with Ab against surface antigens vs AE with Ab against intracellular antigens. The timing of neuroimaging after the onset of symptoms is also considered.

Conclusions

From a systematic review of the literature, it seems that some specific metabolic patterns correlate with the presence of specific Ab, such as a cerebral posterior hypometabolism in anti-NMDAR encephalitis, and a mesiotemporal hypermetabolism (associated with hyperintensities and swollen structures on MRI T2) in encephalitis with LGI1 and onconeural Ab. To ascertain the prognostic value of FDG-PET and its role in driving therapy, larger (preferably longitudinal) studies are needed on age-matched, untreated patients with the same Ab status, who undergo imaging at a similar time after the onset of their symptoms. This would enable a systematic correlation between MRI and FDG-PET findings, and help to clarify a number of unsolved clinical and technical issues.

Keywords

Autoimmune encephalitis PET/CT PET/MRI MRI Paraneoplastic 

Notes

Funding

This study was not funded by any grants.

Compliance with ethical standards

Conflict of interest

DC received consultant honoraria and a liberal donation from Piramal Imaging irrelevant to the aims of the paper. The other authors have no conflicts of interest to disclose.

Statement of human rights

Being a review, this statement is not mandatory.

References

  1. 1.
    Corsellis JA, Goldberg GJ, Norton AR (1968) “Limbic encephalitis” and its association with carcinoma. Brain 91:481–496CrossRefPubMedGoogle Scholar
  2. 2.
    Dalmau J (2016) NMDA receptor encephalitis and other antibody-mediated disorders of the synapse: the 2016 Cotzias lecture. Neurology 87:2471–2482CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Zuliani L, Graus F, Giometto B, Bien C, Vincent A (2012) Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J Neurol Neurosurg Psychiatry 83:638–645CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T et al (2016) A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 15:391–404CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Baumgartner A, Rauer S, Mader I, Meyer PT (2013) Cerebral FDG-PET and MRI findings in autoimmune limbic encephalitis: correlation with autoantibody types. J Neurol 260:2744–2753CrossRefPubMedGoogle Scholar
  6. 6.
    Wegner F, Wilke F, Raab P, Ben Tayeb S, Boeck A-L, Haense C et al (2014) Anti-leucine rich glioma inactivated 1 protein and anti-N-methyl-d-aspartate receptor encephalitis show distinct patterns of brain glucose metabolism in 18F-fluoro-2-deoxy-d-glucose positron emission tomography. BMC Neurol 14:136CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Lagarde S, Lepine A, Caietta E, Pelletier F, Boucraut J, Chabrol B et al (2016) Cerebral (18)fluorodeoxy-glucose positron emission tomography in paediatric anti N-methyl-d-aspartate receptor encephalitis: a case series. Brain Dev 38:461–470CrossRefPubMedGoogle Scholar
  8. 8.
    Leypoldt F, Buchert R, Kleiter I, Marienhagen J, Gelderblom M, Magnus T et al (2012) Fluorodeoxyglucose positron emission tomography in anti-N-methyl-d-aspartate receptor encephalitis: distinct pattern of disease. J Neurol Neurosurg Psychiatry 83:681–686CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Probasco JC, Solnes L, Nalluri A, Cohen J, Jones KM, Zan E et al (2018) Decreased occipital lobe metabolism by FDG-PET/CT: An anti-NMDA receptor encephalitis biomarker. Neurol Neuroimmunol Neuroinflamm 5:e413CrossRefPubMedGoogle Scholar
  10. 10.
    Yuan J, Guan H, Zhou X, Niu N, Li F, Cui L et al (2016) Changing brain metabolism patterns in patients with ANMDARE: serial 18F-FDG PET/CT findings. Clin Nucl Med 41:366–370CrossRefPubMedGoogle Scholar
  11. 11.
    Wang R, Lai X-H, Liu X, Li Y-J, Chen C, Li C, et al. Brain magnetic resonance-imaging findings of anti-N-methyl-d-aspartate receptor encephalitis: a cohort follow-up study in Chinese patients. J Neurol. 2017. http://www.ncbi.nlm.nih.gov/pubmed/29249055
  12. 12.
    Celicanin M, Blaabjerg M, Maersk-Moller C, Beniczky S, Marner L, Thomsen C et al (2017) Autoimmune encephalitis associated with voltage-gated potassium channels-complex and leucine-rich glioma-inactivated 1 antibodies—a national cohort study. Eur J Neurol 24:999–1005CrossRefPubMedGoogle Scholar
  13. 13.
    Shin Y-W, Lee S-T, Shin J-W, Moon J, Lim J-A, Byun J-I et al (2013) VGKC-complex/LGI1-antibody encephalitis: clinical manifestations and response to immunotherapy. J Neuroimmunol 265:75–81CrossRefPubMedGoogle Scholar
  14. 14.
    Chen Y, Xing X-W, Zhang J-T, Wang R-X, Zhao W, Tan Q-C et al (2016) Autoimmune encephalitis mimicking sporadic Creutzfeldt-Jakob disease: a retrospective study. J Neuroimmunol 295–296:1–8CrossRefPubMedGoogle Scholar
  15. 15.
    Newey CR, Sarwal A, Hantus S (2016) [(18)F]-fluoro-deoxy-glucose positron emission tomography scan should be obtained early in cases of autoimmune encephalitis. Autoimmun Dis 2016:9450452Google Scholar
  16. 16.
    Kotsenas AL, Watson RE, Pittock SJ, Britton JW, Hoye SL, Quek AML et al (2014) MRI findings in autoimmune voltage-gated potassium channel complex encephalitis with seizures: one potential etiology for mesial temporal sclerosis. AJNR Am J Neuroradiol 35:84–89CrossRefPubMedGoogle Scholar
  17. 17.
    Finke C, Prüss H, Heine J, Reuter S, Kopp UA, Wegner F et al (2017) Evaluation of cognitive deficits and structural hippocampal damage in encephalitis with leucine-rich, glioma-inactivated 1 antibodies. JAMA Neurol 74:50–59PubMedGoogle Scholar
  18. 18.
    Probasco JC, Solnes L, Nalluri A, Cohen J, Jones KM, Zan E et al (2017) Abnormal brain metabolism on FDG-PET/CT is a common early finding in autoimmune encephalitis. Neurol Neuroimmunol Neuroinflamm 4:e352CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Solnes LB, Jones KM, Rowe SP, Pattanayak P, Nalluri A, Venkatesan A et al (2017) Diagnostic value of 18F-FDG PET/CT versus MRI in the setting of antibody-specific autoimmune encephalitis. J Nucl Med 58:1307–1313CrossRefPubMedGoogle Scholar
  20. 20.
    Fisher RE, Patel NR, Lai EC, Schulz PE (2012) Two different 18F-FDG brain PET metabolic patterns in autoimmune limbic encephalitis. Clin Nucl Med 37:e213–e218CrossRefPubMedGoogle Scholar
  21. 21.
    Ances BM, Vitaliani R, Taylor RA, Liebeskind DS, Voloschin A, Houghton DJ et al (2005) Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain 128:1764–1777CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Kim T-J, Lee S-T, Shin J-W, Moon J, Lim J-A, Byun J-I et al (2014) Clinical manifestations and outcomes of the treatment of patients with GABAB encephalitis. J Neuroimmunol 270:45–50CrossRefPubMedGoogle Scholar
  23. 23.
    Constantinescu R, Krýsl D, Bergquist F, Andrén K, Malmeström C, Asztély F et al (2016) Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long-term outcome in patients with autoimmune encephalitis. Eur J Neurol 23:796–806CrossRefPubMedGoogle Scholar
  24. 24.
    Malter MP, Helmstaedter C, Urbach H, Vincent A, Bien CG (2010) Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol 67:470–478CrossRefPubMedGoogle Scholar
  25. 25.
    Dalmau J, Graus F, Villarejo A, Posner JB, Blumenthal D, Thiessen B et al (2004) Clinical analysis of anti-Ma2-associated encephalitis. Brain 127:1831–1844CrossRefPubMedGoogle Scholar
  26. 26.
    Masangkay N, Basu S, Moghbel M, Kwee T, Alavi A (2014) Brain 18F-FDG-PET characteristics in patients with paraneoplastic neurological syndrome and its correlation with clinical and MRI findings. Nucl Med Commun 35:1038–1046CrossRefPubMedGoogle Scholar
  27. 27.
    Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J (2000) Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 123(Pt 7):1481–1494CrossRefPubMedGoogle Scholar
  28. 28.
    Urbach H, Soeder BM, Jeub M, Klockgether T, Meyer B, Bien CG (2006) Serial MRI of limbic encephalitis. Neuroradiology 48:380–386CrossRefPubMedGoogle Scholar
  29. 29.
    Morbelli S, Arbizu J, Booij J, Chen M-K, Chetelat G, Cross DJ et al (2017) The need of standardization and of large clinical studies in an emerging indication of [18F]FDG PET: the autoimmune encephalitis. Eur J Nucl Med Mol Imaging 44:353–357CrossRefPubMedGoogle Scholar
  30. 30.
    Cecchin D, Barthel H, Poggiali D, Cagnin A, Tiepolt S, Zucchetta P et al (2017) A new integrated dual time-point amyloid PET/MRI data analysis method. Eur J Nucl Med Mol Imaging 44:2060–2072CrossRefPubMedGoogle Scholar
  31. 31.
    Kojima G, Inaba M, Bruno MK (2014) PET-positive extralimbic presentation of anti-glutamic acid decarboxylase antibody-associated encephalitis. Epileptic Disord. 16:358–361PubMedGoogle Scholar
  32. 32.
    Basu S, Alavi A (2008) Role of FDG-PET in the clinical management of paraneoplastic neurological syndrome: detection of the underlying malignancy and the brain PET-MRI correlates. Mol Imaging Biol 10:131–137CrossRefPubMedGoogle Scholar
  33. 33.
    Heine J, Prüss H, Bartsch T, Ploner CJ, Paul F, Finke C (2015) Imaging of autoimmune encephalitis—relevance for clinical practice and hippocampal function. Neuroscience 309:68–83CrossRefPubMedGoogle Scholar
  34. 34.
    van Coevorden-Hameete MH, de Graaff E, Titulaer MJ, Hoogenraad CC, Sillevis Smitt PAE (2014) Molecular and cellular mechanisms underlying anti-neuronal antibody mediated disorders of the central nervous system. Autoimmun Rev 13:299–312CrossRefPubMedGoogle Scholar
  35. 35.
    Plantone D, Renna R, Grossi D, Plantone F, Iorio R (2013) Teaching NeuroImages: basal ganglia involvement in facio-brachial dystonic seizures associated with LGI1 antibodies. Neurology 80:e183–e184CrossRefPubMedGoogle Scholar
  36. 36.
    Lee BY, Newberg AB, Liebeskind DS, Kung J, Alavi A (2004) FDG-PET findings in patients with suspected encephalitis. Clin Nucl Med 29:620–625CrossRefPubMedGoogle Scholar
  37. 37.
    Bien CG, Vincent A, Barnett MH, Becker AJ, Blümcke I, Graus F et al (2012) Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain 135:1622–1638CrossRefPubMedGoogle Scholar
  38. 38.
    García Vicente AM, Delgado-Bolton RC, Amo-Salas M, López-Fidalgo J, Caresia Aróztegui AP, García Garzón JR et al (2017) 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of malignancy in patients with paraneoplastic neurological syndrome: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 44:1575–1587CrossRefPubMedGoogle Scholar
  39. 39.
    Trevino-Peinado C, Arbizu J, Irimia P, Riverol M, Martínez-Vila E (2015) Monitoring the effect of immunotherapy in autoimmune limbic encephalitis using 18F-FDG PET. Clin Nucl Med 40:e441–e443CrossRefPubMedGoogle Scholar
  40. 40.
    Fulham MJ, Brunetti A, Aloj L, Raman R, Dwyer AJ, Di Chiro G (1995) Decreased cerebral glucose metabolism in patients with brain tumors: an effect of corticosteroids. J Neurosurg 83:657–664CrossRefPubMedGoogle Scholar
  41. 41.
    Morbelli S, Garibotto V, Van De Giessen E, Arbizu J, Chételat G, Drezgza A et al (2015) A Cochrane review on brain [18F]FDG PET in dementia: limitations and future perspectives. Eur J Nucl Med Mol Imaging 42:1487–1491CrossRefPubMedGoogle Scholar
  42. 42.
    Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frölich L et al (2002) Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 17:302–316CrossRefPubMedGoogle Scholar
  43. 43.
    Dodich A, Cerami C, Iannaccone S, Marcone A, Alongi P, Crespi C et al (2016) Neuropsychological and FDG-PET profiles in VGKC autoimmune limbic encephalitis. Brain Cogn 108:81–87CrossRefPubMedGoogle Scholar
  44. 44.
    Solomon T, Michael BD, Smith PE, Sanderson F, Davies NWS, Hart IJ et al (2012) Management of suspected viral encephalitis in adults—association of british neurologists and british infection association national guidelines. J Infect 64:347–373CrossRefPubMedGoogle Scholar
  45. 45.
    Bastiaansen AEM, van Sonderen A, Titulaer MJ (2017) Autoimmune encephalitis with anti-leucine-rich glioma-inactivated 1 or anti-contactin-associated protein-like 2 antibodies (formerly called voltage-gated potassium channel-complex antibodies). Curr Opin Neurol 30:302–309CrossRefPubMedGoogle Scholar
  46. 46.
    van Sonderen A, Thijs RD, Coenders EC, Jiskoot LC, Sanchez E, de Bruijn MAAM et al (2016) Anti-LGI1 encephalitis: clinical syndrome and long-term follow-up. Neurology 87:1449–1456CrossRefPubMedGoogle Scholar
  47. 47.
    Joubert B, Saint-Martin M, Noraz N, Picard G, Rogemond V, Ducray F et al (2016) Characterization of a subtype of autoimmune encephalitis with anti-contactin-associated protein-like 2 antibodies in the cerebrospinal fluid, prominent limbic symptoms, and seizures. JAMA Neurol 73:1115–1124CrossRefPubMedGoogle Scholar
  48. 48.
    van Sonderen A, Ariño H, Petit-Pedrol M, Leypoldt F, Körtvélyessy P, Wandinger K-P et al (2016) The clinical spectrum of Caspr2 antibody-associated disease. Neurology 87:521–528CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Lancaster E, Lai M, Peng X, Hughes E, Constantinescu R, Raizer J et al (2010) Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 9:67–76CrossRefPubMedGoogle Scholar
  50. 50.
    Höftberger R, van Sonderen A, Leypoldt F, Houghton D, Geschwind M, Gelfand J et al (2015) Encephalitis and AMPA receptor antibodies: novel findings in a case series of 22 patients. Neurology. 84:2403–2412CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Spatola M, Petit-Pedrol M, Simabukuro MM, Armangue T, Castro FJ, Barcelo Artigues MI et al (2017) Investigations in GABAA receptor antibody-associated encephalitis. Neurology 88:1012–1020CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Flanagan EP, Kotsenas AL, Britton JW, McKeon A, Watson RE, Klein CJ et al (2015) Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures. Neurol Neuroimmunol Neuroinflamm 2:e161CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Vitaliani R, Mason W, Ances B, Zwerdling T, Jiang Z, Dalmau J (2005) Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Ann Neurol 58:594–604CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Miller TD, Chong TT-J, Aimola Davies AM, Ng TWC, Johnson MR, Irani SR et al (2017) Focal CA3 hippocampal subfield atrophy following LGI1 VGKC-complex antibody limbic encephalitis. Brain. 140:1212–1219CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Iizuka T, Yoshii S, Kan S, Hamada J, Dalmau J, Sakai F et al (2010) Reversible brain atrophy in anti-NMDA receptor encephalitis: a long-term observational study. J. Neurol. 257:1686–1691CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Park S, Choi H, Cheon GJ, Wook Kang K, Lee DS (2015) 18F-FDG PET/CT in anti-LGI1 encephalitis: initial and follow-up findings. Clin Nucl Med 40:156–158CrossRefPubMedGoogle Scholar

Copyright information

© Italian Association of Nuclear Medicine and Molecular Imaging 2018

Authors and Affiliations

  1. 1.Nuclear Medicine Unit, Department of Health Sciences (DISSAL)University of Genova, San Martino HospitalGenoaItaly
  2. 2.Neurology UnitULSS Euganea-PadovaPaduaItaly
  3. 3.Neuroradiology Unit, Department of Medicine-DIMEDPadova University HospitalPaduaItaly
  4. 4.Nuclear Medicine Unit, Department of Medicine-DIMEDPadova University HospitalPaduaItaly
  5. 5.Padua Neuroscience CenterUniversity of PaduaPaduaItaly

Personalised recommendations